La descripción de las pandemias que ha sufrido la humanidad, es tan antigua como su historia. El primer texto que describe una epidemia es el papiro de Ebers, encontrado en una tumba de Tebas y tiene 3.500 años (1). A partir de entonces muchas otras epidemias se han presentado y tal vez dos de las más recordadas, por ocasionar una alta tasa de mortalidad, son la peste negra o muerte negra que afectó a Eurasia en el siglo XIV (2) y la de 1918 conocida como “la gripa española” con cerca de 500 millones de personas infectadas (un tercio de la población mundial) y cerca de 50 millones de muertes en el mundo (3).
{"title":"Pandemia de la covid19 y cáncer en el Instituto Nacional de Cancerología –ESE: Cómo actuar pronto y seguro","authors":"Sonia Isabel Cuervo Maldonado","doi":"10.35509/01239015.698","DOIUrl":"https://doi.org/10.35509/01239015.698","url":null,"abstract":"La descripción de las pandemias que ha sufrido la humanidad, es tan antigua como su historia. El primer texto que describe una epidemia es el papiro de Ebers, encontrado en una tumba de Tebas y tiene 3.500 años (1). A partir de entonces muchas otras epidemias se han presentado y tal vez dos de las más recordadas, por ocasionar una alta tasa de mortalidad, son la peste negra o muerte negra que afectó a Eurasia en el siglo XIV (2) y la de 1918 conocida como “la gripa española” con cerca de 500 millones de personas infectadas (un tercio de la población mundial) y cerca de 50 millones de muertes en el mundo (3).","PeriodicalId":42496,"journal":{"name":"Revista Colombiana de Cancerologia","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2020-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42630997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Juan Alejandro Ospina Idárraga, Humberto Martínez-Cordero, Henry Idrobo Quintero, Conrad Ortiz Alfaro, Lina María Martínez Correa, J. García, Luis Malpica, J. Castillo, M. A. Torres, L. Villela, Myrna G Candelaria, Alana Von Glasenapp, B. Beltrán, Sally Paredes, D. E. Castro, Virginia Prates, Marcos Di Stefano, E. Riva, Virginia Abello Polo, Juan Choque, Camila Peña, Christine Rojas, Fabiola Valvert Gamboa, Lorena Fiad
In December 2019, the cause of COVID-19 disease, SARS-CoV2 virus was detected for the first time in China. The virus spread quickly through Europe and Asia, and a couple months after arrived Latin America. Elderly patients and those with chronic disease, including cancer, have high risk of mortatily because of COVID-19. Consequently, many doubts arise in the group of health professionals in charge of cancer treatment during the pandemic because they must handle risk-benefit of providing treatment to patients who are at the base with an increased risk for manifestations derived from COVID-19. In this consensus we propose recommendations for hematology professionals who provide treatment to patients with any type of lymphoma, looking to clarify the clinical picture during the pandemic
{"title":"Consenso del Grupo de Estudio Latinoamericano de Linfoproliferativos (GELL) para el manejo del Linfoma en estado de Pandemia SARS CoV-2 / COVID 19","authors":"Juan Alejandro Ospina Idárraga, Humberto Martínez-Cordero, Henry Idrobo Quintero, Conrad Ortiz Alfaro, Lina María Martínez Correa, J. García, Luis Malpica, J. Castillo, M. A. Torres, L. Villela, Myrna G Candelaria, Alana Von Glasenapp, B. Beltrán, Sally Paredes, D. E. Castro, Virginia Prates, Marcos Di Stefano, E. Riva, Virginia Abello Polo, Juan Choque, Camila Peña, Christine Rojas, Fabiola Valvert Gamboa, Lorena Fiad","doi":"10.35509/01239015.690","DOIUrl":"https://doi.org/10.35509/01239015.690","url":null,"abstract":"In December 2019, the cause of COVID-19 disease, SARS-CoV2 virus was detected for the first time in China. The virus spread quickly through Europe and Asia, and a couple months after arrived Latin America. Elderly patients and those with chronic disease, including cancer, have high risk of mortatily because of COVID-19. Consequently, many doubts arise in the group of health professionals in charge of cancer treatment during the pandemic because they must handle risk-benefit of providing treatment to patients who are at the base with an increased risk for manifestations derived from COVID-19. In this consensus we propose recommendations for hematology professionals who provide treatment to patients with any type of lymphoma, looking to clarify the clinical picture during the pandemic","PeriodicalId":42496,"journal":{"name":"Revista Colombiana de Cancerologia","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2020-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42668065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Humberto Martinez-Codero, L. Martínez, Juan Alejandro Ospina Idárraga, Guillermo J Ruiz Argüelles, Virginia Abello Polo, Camila Peña Ojeda, Macarena Roa, Carlos Fernández de Larrea, Rosa Olday Ríos Jiménez, D. Fantl, Natalia Schutz, E. Riva, Fiorella Villano, Henry Idrobo, V. Bove, Manuel Antonio Granja Morá, M. Zamora
COVID-19 disease was detected at the end of 2019 in Wuhan, China. Due it´s quickly spread was declared a health emergency initially and after identifying cases outside China with indigenous transmission, characterized by considerably high mortality in countries such as Italy and Spain, it was declared a pandemic by the World Health Organization. It has been shown that older patients with a history of chronic diseases including cancer develop severe disease, presenting a higher risk of mortality from SARS-CoV2 / COVID-19. This is especially important in the handle of patients with Multiple Myeloma (MM), generating new challenges, improvement and learning opportunities for Medical group, that contribute to the risk-benefit analysis of immunosuppressive treatment for this type of pathology. The consensus aims to provide guidance for the management of patients with MM in this time where the health professional requires information to carry out efficient therapies in patient care.
{"title":"Consenso del Grupo Latinoamericano de estudio de Mieloma Múltiple (MM) GELAMM para el manejo del MM en estado de Pandemia SARS CoV-2 / COVID 19","authors":"Humberto Martinez-Codero, L. Martínez, Juan Alejandro Ospina Idárraga, Guillermo J Ruiz Argüelles, Virginia Abello Polo, Camila Peña Ojeda, Macarena Roa, Carlos Fernández de Larrea, Rosa Olday Ríos Jiménez, D. Fantl, Natalia Schutz, E. Riva, Fiorella Villano, Henry Idrobo, V. Bove, Manuel Antonio Granja Morá, M. Zamora","doi":"10.35509/01239015.656","DOIUrl":"https://doi.org/10.35509/01239015.656","url":null,"abstract":"COVID-19 disease was detected at the end of 2019 in Wuhan, China. Due it´s quickly spread was declared a health emergency initially and after identifying cases outside China with indigenous transmission, characterized by considerably high mortality in countries such as Italy and Spain, it was declared a pandemic by the World Health Organization. It has been shown that older patients with a history of chronic diseases including cancer develop severe disease, presenting a higher risk of mortality from SARS-CoV2 / COVID-19. This is especially important in the handle of patients with Multiple Myeloma (MM), generating new challenges, improvement and learning opportunities for Medical group, that contribute to the risk-benefit analysis of immunosuppressive treatment for this type of pathology. \u0000The consensus aims to provide guidance for the management of patients with MM in this time where the health professional requires information to carry out efficient therapies in patient care.","PeriodicalId":42496,"journal":{"name":"Revista Colombiana de Cancerologia","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2020-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46289232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
María Antonia Meroño Saura, M. D. Perez, Francisco Ayala de la Peña, Taida María Rodríguez Martínez, Celia Fernández Zamora, J. L. Villar
Background and objective: the use of off-label drugs is the use of medications in conditions other than those included in its prescribing information. The objective of this paper is to analyze the off-label drugs applications and their results, performed by the Oncology and Hematology services in a second level hospital. Materials and methods: A retrospective observational study of all requests for "off label" drugs received by the Pharmacy Service was carried out. The drugs were classified according to economic impact, a classification according to the type of drug and the reason for the request and according to the degree of evidence. The demographic, diagnostic and treatment data of the patients were analyzed for each request. A follow-up of adverse effects, median progression-free survival and median overall survival is presented. Results: 85 treatment requests were approved. Most of the treatments were high impact, mainly aimed at rare pathologies and last treatment options. 22% of the requests had a high degree of evidence. Progression free survival (PFS) and overall survival (OS) were 6.6 (95% CI 5.2-8) and 9.7 months (95% CI 8.2-11.2). 18.7% of patients had grade 3-4 toxicity when receiving treatment. Conclusions: Despite the heterogeneity of the pathologies, and the low evidence, the results obtained in SLP and SG, together with the low toxicity, force us to continue advancing in the evaluation of this type of treatments.
背景和目的:说明书外药物的使用是指在处方信息以外的条件下使用药物。本文的目的是分析超说明书药物的应用和他们的结果，执行肿瘤和血液服务在二级医院。材料和方法:对药学服务收到的所有“超说明书”药品申请进行回顾性观察研究。药品按经济影响进行分类，按药品种类和请求理由进行分类，按证据程度进行分类。针对每项要求分析患者的人口学、诊断和治疗数据。对不良反应、中位无进展生存期和中位总生存期进行随访。结果:85例治疗请求获得批准。大多数治疗方法疗效高，主要针对罕见病变和最后治疗方案。22%的请求具有高度证据。无进展生存期(PFS)和总生存期(OS)分别为6.6个月(95% CI 5.2-8)和9.7个月(95% CI 8.2-11.2)。18.7%的患者在接受治疗时毒性为3-4级。结论:尽管病理异质性和证据不足，但SLP和SG所获得的结果，以及低毒性，迫使我们继续推进对这类治疗的评估。
{"title":"Análisis del uso de fármacos fuera de indicación autorizada en hematología y oncología","authors":"María Antonia Meroño Saura, M. D. Perez, Francisco Ayala de la Peña, Taida María Rodríguez Martínez, Celia Fernández Zamora, J. L. Villar","doi":"10.35509/01239015.32","DOIUrl":"https://doi.org/10.35509/01239015.32","url":null,"abstract":"Background and objective: the use of off-label drugs is the use of medications in conditions other than those included in its prescribing information. The objective of this paper is to analyze the off-label drugs applications and their results, performed by the Oncology and Hematology services in a second level hospital. \u0000Materials and methods: A retrospective observational study of all requests for \"off label\" drugs received by the Pharmacy Service was carried out. The drugs were classified according to economic impact, a classification according to the type of drug and the reason for the request and according to the degree of evidence. The demographic, diagnostic and treatment data of the patients were analyzed for each request. A follow-up of adverse effects, median progression-free survival and median overall survival is presented. \u0000Results: 85 treatment requests were approved. Most of the treatments were high impact, mainly aimed at rare pathologies and last treatment options. 22% of the requests had a high degree of evidence. Progression free survival (PFS) and overall survival (OS) were 6.6 (95% CI 5.2-8) and 9.7 months (95% CI 8.2-11.2). 18.7% of patients had grade 3-4 toxicity when receiving treatment. \u0000Conclusions: Despite the heterogeneity of the pathologies, and the low evidence, the results obtained in SLP and SG, together with the low toxicity, force us to continue advancing in the evaluation of this type of treatments.","PeriodicalId":42496,"journal":{"name":"Revista Colombiana de Cancerologia","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2020-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43981823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
El término más conocido es uso off label de medicamentos, sin embargo, en un intento por castellanizarlo se le ha denominado también uso fuera de indicación, indicación no habitual, no oficial, no autorizada, no aprobada, uso alternativo o uso desvirtuado, y para el caso de Colombia se acuño el término Uso No Indicado en el Registro Sanitario (UNIRS). Todos estos conceptos tienen en común la información existente en el registro sanitario: indicación, dosis, vías de administración y población. Por lo tanto, el uso off label (de ahora en adelante UNIRS) de un medicamento varía dependiendo de las condiciones bajo las cuales fue aprobada su comercialización en cada país (1). En el caso de Colombia, existen algunos problemas al aplicar estrictamente esta definición, ya que la dosis no está incluida en la mayoría de los registros sanitarios, y la indicación terapéutica en ocasiones se confunde con el efecto farmacológico, no se concreta a una indicación en particular o puede variar de un registro a otro.
{"title":"El uso off label de medicamento: ¿buena o mala práctica?","authors":"José Julián López G","doi":"10.35509/01239015.421","DOIUrl":"https://doi.org/10.35509/01239015.421","url":null,"abstract":"El término más conocido es uso off label de medicamentos, sin embargo, en un intento por castellanizarlo se le ha denominado también uso fuera de indicación, indicación no habitual, no oficial, no autorizada, no aprobada, uso alternativo o uso desvirtuado, y para el caso de Colombia se acuño el término Uso No Indicado en el Registro Sanitario (UNIRS). Todos estos conceptos tienen en común la información existente en el registro sanitario: indicación, dosis, vías de administración y población. Por lo tanto, el uso off label (de ahora en adelante UNIRS) de un medicamento varía dependiendo de las condiciones bajo las cuales fue aprobada su comercialización en cada país (1). \u0000En el caso de Colombia, existen algunos problemas al aplicar estrictamente esta definición, ya que la dosis no está incluida en la mayoría de los registros sanitarios, y la indicación terapéutica en ocasiones se confunde con el efecto farmacológico, no se concreta a una indicación en particular o puede variar de un registro a otro. ","PeriodicalId":42496,"journal":{"name":"Revista Colombiana de Cancerologia","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2020-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42633358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Adriana Valdelamar Jiménez, B. Molina, Luisa Rodríguez, Ricardo Sánchez Pedraza
Introduction: Measuring quality of life in patients having advanced cancer using scales allows to objectively evaluate a prioritary outcome in this group of patients. Objective: to translate and adapt the FACIT-Pal scale cross-culturally in patients with advanced cancer in Colombia. Methods: The study was carried out according to the steps suggested by the FACIT group for translation and transcultural adaptation of scales. A pilot test was applied to 10 Colombian patients who attended the palliative care service of the Instituto Nacional de Cancerologia E.S.E. Results: in the adaptation the items Pal-1, 5,10,12 and 14 were modified in the reconciled version and there were no changes in the translation of the instructions and answer options; after the pilot test, the items that were confusing for the patients were Pal-5 and 9 and no items were offensive. Conclusions: A transculturally adapted version of the FACIT-Pal was generated; this version can be validated in patients diagnosed with advanced cancer in Colombia.
{"title":"Traducción y adaptación transcultural de la escala FACIT-PAL para medir la calidad de vida en pacientes con cáncer avanzado en Colombia","authors":"Adriana Valdelamar Jiménez, B. Molina, Luisa Rodríguez, Ricardo Sánchez Pedraza","doi":"10.35509/01239015.13","DOIUrl":"https://doi.org/10.35509/01239015.13","url":null,"abstract":"Introduction: Measuring quality of life in patients having advanced cancer using scales allows to objectively evaluate a prioritary outcome in this group of patients. \u0000Objective: to translate and adapt the FACIT-Pal scale cross-culturally in patients with advanced cancer in Colombia. \u0000Methods: The study was carried out according to the steps suggested by the FACIT group for translation and transcultural adaptation of scales. A pilot test was applied to 10 Colombian patients who attended the palliative care service of the Instituto Nacional de \u0000 \u0000Cancerologia E.S.E. \u0000Results: in the adaptation the items Pal-1, 5,10,12 and 14 were modified in the reconciled version and there were no changes in the translation of the instructions and answer options; after the pilot test, the items that were confusing for the patients were Pal-5 and 9 and no items were offensive. \u0000Conclusions: A transculturally adapted version of the FACIT-Pal was generated; this version can be validated in patients diagnosed with advanced cancer in Colombia.","PeriodicalId":42496,"journal":{"name":"Revista Colombiana de Cancerologia","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2020-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42738308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M LuisF.Fierro, C JesúsO.Sánchez, G MireyaTapiero, R AndrésFlórez, D HenryVargas, C ClaudiaCórdoba
Los tumores neuroendocrinos pancreáticos (TNEsP) son un grupo poco frecuente de neoplasias, pueden ser funcionales, causando síndromes clínicos diversos, o no funcionales, con síntomas secundarios a invasión a estructuras cercanas o enfermedad metastasica (1). Se presenta el caso de una paciente de 55 años con insulinoma maligno con compromiso metastasico extenso, no candidata a intervención quirúrgica, con hipoglucemia de difícil manejo sin respuesta a tratamiento con diazóxido y prednisolona, que requirió manejo con quimioterapia y embolización de metástasis hepáticas, con posterior mejoría clínica, estabilidad de la enfermedad por imágenes diagnósticas y retiro de medicamentos para manejo hipoglucemia. En seguimiento presenta síntomas de hiperglucemia con HbA1c en 12%, con lo cual se diagnosticó diabetes mellitus de novo y se inició manejo con insulina.
{"title":"Diabetes posterior a tratamiento no quirúrgico de un insulinoma maligno: reporte de caso y revisión literatura","authors":"M LuisF.Fierro, C JesúsO.Sánchez, G MireyaTapiero, R AndrésFlórez, D HenryVargas, C ClaudiaCórdoba","doi":"10.35509/01239015.138","DOIUrl":"https://doi.org/10.35509/01239015.138","url":null,"abstract":"Los tumores neuroendocrinos pancreáticos (TNEsP) son un grupo poco frecuente de neoplasias, pueden ser funcionales, causando síndromes clínicos diversos, o no funcionales, con síntomas secundarios a invasión a estructuras cercanas o enfermedad metastasica (1). Se presenta el caso de una paciente de 55 años con insulinoma maligno con compromiso metastasico extenso, no candidata a intervención quirúrgica, con hipoglucemia de difícil manejo sin respuesta a tratamiento con diazóxido y prednisolona, que requirió manejo con quimioterapia y embolización de metástasis hepáticas, con posterior mejoría clínica, estabilidad de la enfermedad por imágenes diagnósticas y retiro de medicamentos para manejo hipoglucemia. En seguimiento presenta síntomas de hiperglucemia con HbA1c en 12%, con lo cual se diagnosticó diabetes mellitus de novo y se inició manejo con insulina. ","PeriodicalId":42496,"journal":{"name":"Revista Colombiana de Cancerologia","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2020-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43669093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Carolina Alvarez Tapias, Luis Guzmán, Sandra Díaz, J. Carreño, Rafael Beltrán, Ricardo Buitrago, C. Carvajal
Materials and Methods: A case-series study was developed to describe the clinical, histological and anatomopathological characteristics of a sample of patients with a diagnosis of de novo metastatic breast cancer or whom presented with pulmonary nodules during their disease that required surgical resection by wedge pulmonary or lobectomy in the INC, between January 1, 2015 and April 30, 2018. Results: Fifty-five cases were included in the study period, of which 26 (47.3%) were breast cancer metastases, 9 (16.4%) were pulmonary primary second, and 1 (1.8%) patient had primary pulmonary cancer and one breast metastasis concomitantly. Another 2 (3.6%) patients had metastases from other organs, one from the rectum and one from the thyroid, while the remaining 17 (30.9%) patients presented a report of benign pulmonary lesions in the pathological anatomy. Conclusion: The presence of pulmonary nodules in patients with breast cancer are not always secondary to metastatic disease. Other etiologies may exist, such as primary pulmonary cancer, metastasis from other cancers, benign lung tumors or infections. Knowing the etiology of pulmonary nodules in patients with breast cancer is crucial to evaluate the therapeutic options .
{"title":"Etiología de nódulos pulmonares en pacientes con cáncer mamario","authors":"Carolina Alvarez Tapias, Luis Guzmán, Sandra Díaz, J. Carreño, Rafael Beltrán, Ricardo Buitrago, C. Carvajal","doi":"10.35509/01239015.81","DOIUrl":"https://doi.org/10.35509/01239015.81","url":null,"abstract":"Materials and Methods: A case-series study was developed to describe the clinical, histological and anatomopathological characteristics of a sample of patients with a diagnosis of de novo metastatic breast cancer or whom presented with pulmonary nodules during their disease that required surgical resection by wedge pulmonary or lobectomy in the INC, between January 1, 2015 and April 30, 2018. \u0000Results: Fifty-five cases were included in the study period, of which 26 (47.3%) were breast cancer metastases, 9 (16.4%) were pulmonary primary second, and 1 (1.8%) patient had primary pulmonary cancer and one breast metastasis concomitantly. Another 2 (3.6%) patients had metastases from other organs, one from the rectum and one from the thyroid, while the remaining 17 (30.9%) patients presented a report of benign pulmonary lesions in the pathological anatomy. \u0000Conclusion: The presence of pulmonary nodules in patients with breast cancer are not always secondary to metastatic disease. Other etiologies may exist, such as primary pulmonary cancer, metastasis from other cancers, benign lung tumors or infections. Knowing the etiology of pulmonary nodules in patients with breast cancer is crucial to evaluate the therapeutic options .","PeriodicalId":42496,"journal":{"name":"Revista Colombiana de Cancerologia","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2020-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46763633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
There are clinical cases operated with the large dorsal breast reconstruction technique 9d, and a surgical procedure is shown that allows a better finish in terms of symmetry, volume and projection. Four cases of late reconstruction are shown, of which 2 were late reconstructions themselves and the other 2 with previous reconstructions with complications (one case of previous TRAM necrosis and another with poor positioning of the prosthesis). The use of a vacuum assisted closure system (negative pressure system), a non-invasive and dynamic system that helps promote healing at the site of the wound, which favors the reduction of the wound area, eliminating excess Auids and stimulating angiogenesis. The 4 cases were treated at the National Cancer Institute of Colombia, the San Diego Clinic and the Villavicencio Departmental Hospital.
{"title":"Reconstrucción Mamaria Tardia Vd","authors":"E. Chaparro, J. Ochoa, José Geles","doi":"10.35509/01239015.53","DOIUrl":"https://doi.org/10.35509/01239015.53","url":null,"abstract":"There are clinical cases operated with the large dorsal breast reconstruction technique 9d, and a surgical procedure is shown that allows a better finish in terms of symmetry, volume and projection. \u0000Four cases of late reconstruction are shown, of which 2 were late reconstructions themselves and the other 2 with previous reconstructions with complications (one case of previous TRAM necrosis and another with poor positioning of the prosthesis). \u0000The use of a vacuum assisted closure system (negative pressure system), a non-invasive and dynamic system that helps promote healing at the site of the wound, which favors the reduction of the wound area, eliminating excess Auids and stimulating angiogenesis. \u0000The 4 cases were treated at the National Cancer Institute of Colombia, the San Diego Clinic and the Villavicencio Departmental Hospital.","PeriodicalId":42496,"journal":{"name":"Revista Colombiana de Cancerologia","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2020-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49560164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：